A Phase 2b Study of Immune Checkpoint Inhibition With or Without Dorgenmeltucel-L (HyperAcute Melanoma) Immunotherapy for Stage IV Melanoma Patients

Trial Profile

A Phase 2b Study of Immune Checkpoint Inhibition With or Without Dorgenmeltucel-L (HyperAcute Melanoma) Immunotherapy for Stage IV Melanoma Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Dorgenmeltucel-L (Primary) ; Ipilimumab; Nivolumab; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 29 Oct 2015 Treatment arms changed from 2 to 6 as reported by ClinicalTrial.gov record.
    • 28 Oct 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Dec 2016 as reported by ClinicalTrial.gov record.
    • 31 May 2014 The trial protocol presented at 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top